"Organoplatinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain platinum as an integral part of the molecule.
| Descriptor ID |
D009944
|
| MeSH Number(s) |
D02.691.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organoplatinum Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organoplatinum Compounds".
This graph shows the total number of publications written about "Organoplatinum Compounds" by people in this website by year, and whether "Organoplatinum Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2006 | 2 | 2 | 4 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 3 | 3 |
| 2016 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Organoplatinum Compounds" by people in Profiles.
-
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81.
-
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep; 76(3):489-498.
-
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
-
Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
-
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
-
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 2014 Sep 10; 14:660.
-
Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea. Cancer. 2015 Jan 01; 121(1):84-92.
-
A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res. 2014 Nov 01; 74(21):5955-62.
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
-
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar; 19(3):266-74.